Clinical Trial Update: IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update noting completion of Phase 1 and Phase 2 studies of an IL-15 dendritic cell vaccine in patients with resected stage III or stage IV melano…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• IL-15 dendritic cell vaccine (interleukin-15 dendritic cell vaccine)

Snippet

Sponsor: Baylor Research Institute | Conditions: Malignant Melanoma Stage III, Malignant Melanoma Stage IV | Phase 1, Phase 2 | Status: COMPLETED